StorytellERdoc
MAY 14, 2020
As an added bonus, we enjoyed the people-watching and marveled at the wide spectrum of personal flaws the other shoppers provided us. I asked, thinking about how amazing our case managers in our ER were. And in those two minutes time, Richard had provided a view to a world different than ours. Giving provides gratitude.
FDA Law Blog
DECEMBER 4, 2023
Houck — Separate decisions by federal district courts in Texas and Puerto Rico in the past two months provide cautionary tales for every pharmacy and wholesale distributor dispensing or distributing controlled substances. Providers should be aware of the other drugs prescribed to their patients. By Larry K. Complaint ¶ 62.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Vascular Physician
APRIL 22, 2024
Unless they are seeing their primary care provider for regular check-ups, they may not be made aware of their high blood pressure until they present for evaluation for another medical condition. Unfortunately, high blood pressure does not always present with symptoms that are noticeable by the patient.
The Clinical Problem Solvers
OCTOBER 23, 2019
The “Clinical Reasoning Corner” will provide an introduction to the topics that keep our reasoning rooted in the core principles of clinical problem solving. Pre and posttest probabilities provide a framework that helps us decide which diagnostic tests to send, interpret their results, and prioritize our differential. More practice?
FDA Law Blog
JANUARY 15, 2024
Let’s just say, the smackdown—er, decision—eviscerates FDA’s approach to regulating flavored e-cigarettes. At an October 2019 Meeting , FDA explained the application process and provided assurances that decisions would be made on each specific product in a submission—not the submission in its entirety.
PEMBlog
MAY 20, 2025
We know that nine out of ten children that go to the ER do not go to children’s hospital ERs. I think it’s very important, almost an obligation, for us to provide outreach and education to our community ED colleagues so that they are given the tools needed to provide the right imaging to the right patient at the right time.
FDA Law Blog
APRIL 26, 2021
At that time, Endo had decided to launch a crush-resistant Opana ER and remove the original Opana ER from the market, which would ultimately render any generic to original Opana ER not substitutable, but Endo needed some time to shift the market to its crush-resistant product. This case remains ongoing.
Expert insights. Personalized for you.
130 
Let's personalize your content